Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Business Wire•30/10/2026•17:38 ET
1
Key Highlights
- ➤Adicet Bio granted one employee options to purchase 1,500 shares at $3.42 per share
- ➤Option vests over four years, beginning with 25% after the employee’s first year
- ➤Award issued under Adicet’s 2022 Inducement Plan under Nasdaq Rule 5635(c)(4)
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on October 30, 2026.
Get started
Create a free account to read the full story.